Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EYPT 
Eyepoint Pharmaceuticals Inc (EYPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: EYPT (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $34.42
1 Year Target Price $34.42
| 9 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 300.87% | Avg. Invested days 46 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 747.86M USD | Price to earnings Ratio - | 1Y Target Price 34.42 |
Price to earnings Ratio - | 1Y Target Price 34.42 | ||
Volume (30-day avg) 13 | Beta 1.75 | 52 Weeks Range 3.91 - 13.98 | Updated Date 08/14/2025 |
52 Weeks Range 3.91 - 13.98 | Updated Date 08/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.69 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.81 | Actual -0.85 |
Profitability
Profit Margin - | Operating Margin (TTM) -1166.83% |
Management Effectiveness
Return on Assets (TTM) -37.79% | Return on Equity (TTM) -73.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 524972949 | Price to Sales(TTM) 14.41 |
Enterprise Value 524972949 | Price to Sales(TTM) 14.41 | ||
Enterprise Value to Revenue 10.12 | Enterprise Value to EBITDA -11.49 | Shares Outstanding 68927400 | Shares Floating 43220253 |
Shares Outstanding 68927400 | Shares Floating 43220253 | ||
Percent Insiders 3.51 | Percent Institutions 109.49 |
Upturn AI SWOT
Eyepoint Pharmaceuticals Inc
Company Overview
History and Background
EyePoint Pharmaceuticals, Inc. was founded in 1987 (as Control Delivery Systems, Inc) and is focused on developing and commercializing innovative ophthalmic products using its proprietary bioerodible drug delivery technologies to improve the lives of patients with eye disorders. They have a history of developing sustained-release drug delivery systems for ophthalmic diseases.
Core Business Areas
- Drug Delivery Technology: Develops and utilizes proprietary Durasert E and Verisome drug delivery platforms for sustained release of therapeutics within the eye.
- Commercial Products: Focuses on the commercialization of products like Yutiq and LexaFilm (currently in development) for treating chronic, sight-threatening eye diseases.
- Research and Development: Continues research into new drug candidates and formulations to expand their product portfolio in ophthalmology.
Leadership and Structure
EyePoint Pharmaceuticals is led by a board of directors and an executive management team. Key executives include the CEO, CFO, and Chief Medical Officer. The organizational structure is typical of a publicly traded pharmaceutical company, with departments dedicated to research, development, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Yutiq: Yutiq (fluocinolone acetonide intravitreal implant) is a sustained-release intravitreal micro-insert indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Competitors include corticosteroid eye drops, oral steroids, and other intravitreal steroid injections like Ozurdex (dexamethasone intravitreal implant) by Allergan/AbbVie. Market share data can fluctuate; therefore it is better to access the latest market report.
- LexaFilm: LexaFilm is a sustained release topically delivered product being developed for the treatment of dry eye disease. Competitors in this space include Restasis (cyclosporine ophthalmic emulsion) and Xiidra (lifitegrast ophthalmic solution). Market share data can fluctuate; therefore it is better to access the latest market report.
Market Dynamics
Industry Overview
The ophthalmic pharmaceutical market is driven by an aging population, increasing prevalence of eye diseases (e.g., diabetic retinopathy, glaucoma, dry eye), and technological advancements in drug delivery. The market is competitive, with many established pharmaceutical companies and emerging biotech firms.
Positioning
EyePoint Pharmaceuticals is positioned as a specialty pharmaceutical company focused on sustained-release drug delivery in ophthalmology. Their competitive advantage lies in their proprietary Durasert E and Verisome drug delivery technologies, which allow for long-term, controlled release of therapeutic agents.
Total Addressable Market (TAM)
The global ophthalmology market is expected to reach hundreds of billions of dollars. EyePoint Pharmaceuticals is positioned to capture a portion of this TAM with its targeted therapies for specific ophthalmic conditions. The exact TAM for their specific product segments depends on factors like disease prevalence and market penetration.
Upturn SWOT Analysis
Strengths
- Proprietary drug delivery technology platforms (Durasert E and Verisome)
- Focus on chronic eye diseases with unmet needs
- Commercialized products (Yutiq) generating revenue
- Pipeline of product candidates in development
- Experienced management team with expertise in ophthalmology
Weaknesses
- Reliance on a limited number of commercial products
- Competition from larger pharmaceutical companies
- Regulatory hurdles and clinical trial risks
- Need to raise capital to fund research and development
- Manufacturing and supply chain dependencies
Opportunities
- Expansion of existing product indications
- Development of new drug candidates for other ophthalmic diseases
- Partnerships and collaborations with other companies
- Geographic expansion into new markets
- Acquisition of complementary technologies or products
Threats
- Competition from generic drugs and biosimilars
- Changes in regulatory requirements
- Clinical trial failures
- Economic downturns
- Product liability claims
Competitors and Market Share
Key Competitors
- ABBV
- ALVR
- REGN
- PFE
Competitive Landscape
EyePoint's drug delivery technology gives it an edge, but it faces stiff competition from major players with larger resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth can be assessed by analyzing revenue growth, product sales, and pipeline development over the past few years.
Future Projections: Future projections are best obtained from analyst reports, which provide estimates for revenue, earnings, and stock price targets. These estimates are based on factors like product sales forecasts, clinical trial results, and market trends.
Recent Initiatives: Recent strategic initiatives include product launches, clinical trial announcements, partnerships, and acquisitions.
Summary
EyePoint Pharmaceuticals is a specialty pharmaceutical company with innovative drug delivery technologies. Its strengths lie in its focus on ophthalmic diseases and its proprietary platforms. However, it faces competition from larger companies and needs to manage regulatory and clinical trial risks. While it has revenue generating products, continued investment into research and development and market expansion are critical for sustainable growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings (10-K, 10-Q), Company website, Press releases, Analyst reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share data can fluctuate and may not be precise. Financial data should be verified from official SEC filings. Consider the source of market share information, because many of the third party sources will have data which is not perfectly aligned. Therefore, it's prudent to consider multiple sources to get an understanding of true market share.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eyepoint Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2005-01-27 | President, CEO & Director Dr. Jay S. Duker M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 165 | Website https://eyepointpharma.com |
Full time employees 165 | Website https://eyepointpharma.com | ||
EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.